CareDx launches AI-driven AlloSure Plus integrated with EPIC Aura

BRISBANE, Calif. - CareDx, Inc. (NASDAQ:CDNA), a $684 million market cap precision medicine company with robust financials including a healthy current ratio of 4.11 and strong revenue growth of 26% over the last twelve months, announced the launch of AlloSure Plus, an artificial intelligence-driven diagnostic platform that integrates donor-derived cell-free DNA analysis with traditional tools to provide personalized rejection risk assessment for transplant patients. According to InvestingPro analysis, the company maintains more cash than debt on its balance sheet, positioning it well for continued innovation.

The platform, previously known as AlloView, will be integrated with EPIC Aura at initial launch sites in the third quarter of 2025, with broader implementation to follow. An international prospective study led by the Paris Transplant Group validated AlloSure Plus using over 2,700 renal transplant biopsies. With the stock currently trading below its Fair Value according to InvestingPro analysis, investors might find interest in the company’s growth trajectory and strong financial health metrics.

The announcement comes as CareDx presents more than 40 studies at the 2025 World Transplant Congress (WTC). Key research highlights include a study of over 4,100 biopsies showing improved sensitivity and specificity for detecting transplant rejection, and data from the KOAR registry revealing that kidney transplant recipients with elevated donor-derived cell-free DNA faced an 8.17-fold increased risk of graft loss at three years.

Another study of 56 recipients of high-risk kidneys demonstrated that longitudinal AlloSure monitoring showed consistently low levels and excellent graft survival, potentially supporting broader utilization of marginal organs.

"Every innovation we advance, from AI diagnostics to transplant quality analytics, is driven by our commitment to improving patient access, outcomes, and care experiences," said John Hanna, President and CEO of CareDx, in the press release.

CareDx will also host a symposium on August 4 featuring transplant care experts from NYU Langone Health, Virginia Commonwealth University, and the Paris Institute of Transplantation to discuss clinical applications of AlloSure.

The company focuses on developing precision medicine solutions for transplant patients and caregivers.

In other recent news, CareDx, Inc. reported an 18% increase in first-quarter revenue year-over-year, totaling $84.7 million. The company also completed a $50 million stock buyback program, which accounts for approximately 5% of its outstanding shares. CareDx ended the first quarter with $231 million in cash, cash equivalents, and marketable securities, maintaining a debt-free status. Additionally, a proposed draft Medicare Local Coverage Determination will continue coverage for molecular surveillance testing for transplant patients, with no immediate changes to existing policies. This draft policy introduces a bundled payment concept and is open for public comment until August 31, 2025.

BTIG analyst Sung Ji Nam revised the price target for CareDx shares to $30, down from $35, while maintaining a Buy rating. This adjustment came after a 9% decline in shares following the company’s first-quarter earnings report, which met expectations. The analyst attributed the market’s reaction to volatility, noting CareDx’s solid fundamentals, including a 12% year-over-year growth in testing volumes.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.